RARE
Price
$36.26
Change
-$0.10 (-0.28%)
Updated
Jul 1 closing price
Capitalization
3.43B
29 days until earnings call
VRDN
Price
$14.47
Change
+$0.49 (+3.51%)
Updated
Jul 1 closing price
Capitalization
1.14B
35 days until earnings call
Interact to see
Advertisement

RARE vs VRDN

Header iconRARE vs VRDN Comparison
Open Charts RARE vs VRDNBanner chart's image
Ultragenyx Pharmaceutical
Price$36.26
Change-$0.10 (-0.28%)
Volume$689.9K
Capitalization3.43B
Viridian Therapeutics
Price$14.47
Change+$0.49 (+3.51%)
Volume$825.27K
Capitalization1.14B
RARE vs VRDN Comparison Chart in %
Loading...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RARE vs. VRDN commentary
Jul 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RARE is a Buy and VRDN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 02, 2025
Stock price -- (RARE: $36.26 vs. VRDN: $14.47)
Brand notoriety: RARE and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RARE: 67% vs. VRDN: 107%
Market capitalization -- RARE: $3.43B vs. VRDN: $1.14B
RARE [@Biotechnology] is valued at $3.43B. VRDN’s [@Biotechnology] market capitalization is $1.14B. The market cap for tickers in the [@Biotechnology] industry ranges from $306.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RARE’s FA Score shows that 0 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • RARE’s FA Score: 0 green, 5 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, both RARE and VRDN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RARE’s TA Score shows that 4 TA indicator(s) are bullish while VRDN’s TA Score has 4 bullish TA indicator(s).

  • RARE’s TA Score: 4 bullish, 6 bearish.
  • VRDN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, VRDN is a better buy in the short-term than RARE.

Price Growth

RARE (@Biotechnology) experienced а -2.42% price change this week, while VRDN (@Biotechnology) price change was -1.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.93%. For the same industry, the average monthly price growth was +32.08%, and the average quarterly price growth was +3.19%.

Reported Earning Dates

RARE is expected to report earnings on Jul 31, 2025.

VRDN is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (-0.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($3.43B) has a higher market cap than VRDN($1.14B). RARE YTD gains are higher at: -13.810 vs. VRDN (-24.517). VRDN has higher annual earnings (EBITDA): -304.76M vs. RARE (-449.9M). VRDN has more cash in the bank: 637M vs. RARE (494M). VRDN has less debt than RARE: VRDN (21.2M) vs RARE (38.3M). RARE has higher revenues than VRDN: RARE (591M) vs VRDN (302K).
RAREVRDNRARE / VRDN
Capitalization3.43B1.14B301%
EBITDA-449.9M-304.76M148%
Gain YTD-13.810-24.51756%
P/E RatioN/AN/A-
Revenue591M302K195,695%
Total Cash494M637M78%
Total Debt38.3M21.2M181%
FUNDAMENTALS RATINGS
RARE vs VRDN: Fundamental Ratings
RARE
VRDN
OUTLOOK RATING
1..100
7066
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
92
Overvalued
PROFIT vs RISK RATING
1..100
10099
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
6058
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a34

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RARE's Valuation (79) in the Biotechnology industry is in the same range as VRDN (92). This means that RARE’s stock grew similarly to VRDN’s over the last 12 months.

VRDN's Profit vs Risk Rating (99) in the Biotechnology industry is in the same range as RARE (100). This means that VRDN’s stock grew similarly to RARE’s over the last 12 months.

VRDN's SMR Rating (97) in the Biotechnology industry is in the same range as RARE (100). This means that VRDN’s stock grew similarly to RARE’s over the last 12 months.

VRDN's Price Growth Rating (58) in the Biotechnology industry is in the same range as RARE (60). This means that VRDN’s stock grew similarly to RARE’s over the last 12 months.

VRDN's P/E Growth Rating (100) in the Biotechnology industry is in the same range as RARE (100). This means that VRDN’s stock grew similarly to RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RAREVRDN
RSI
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 7 days ago
76%
Bullish Trend 16 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSTKX19.34N/A
N/A
Goldman Sachs International Eq Inc Inv
ATWCX24.13N/A
N/A
AB Tax-Managed Wealth Apprec Strat C
JFRNX62.42N/A
N/A
Janus Henderson Forty N
EIISX16.70N/A
N/A
Parametric International Equity I
DLCEX22.84N/A
N/A
Dana Large Cap Equity Investor

RARE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been loosely correlated with CRNX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if RARE jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
-0.28%
CRNX - RARE
51%
Loosely correlated
-1.15%
RVMD - RARE
51%
Loosely correlated
+0.27%
COGT - RARE
50%
Loosely correlated
+0.56%
RNA - RARE
49%
Loosely correlated
+0.21%
NRIX - RARE
49%
Loosely correlated
+2.81%
More

VRDN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with AURA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then AURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
+3.51%
AURA - VRDN
50%
Loosely correlated
N/A
DNLI - VRDN
49%
Loosely correlated
-0.29%
DSGN - VRDN
48%
Loosely correlated
+4.45%
TERN - VRDN
47%
Loosely correlated
+3.22%
BEAM - VRDN
47%
Loosely correlated
+3.06%
More